
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses cessation of chronic myeloid leukemia (CML) treatment for therapy-free remission.Â
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses cessation of chronic myeloid leukemia (CML) treatment for therapy-free remission.Â
Mauro says patients with CML are often concerned about how long they have to stay on medication.






